AIM: The purpose of this study was to investigate the hitherto undescribed effects of botulinum toxin A injected into the lacrimal gland in @entity1 with functional @entity9467 . METHODS: A prospective non-comparative interventional case series study was designed to include @entity1 with functional @entity9467 who presented to the Oculoplastic unit at the Wolverhampton and Midland Counties Eye Infirmary. Botulinum toxin A (2.5-5 units) was injected into the palpebral lobe of the lacrimal gland on the worst affected side via a transconjunctival approach under topical anaesthesia. @entity1 underwent a Schirmer test and provided a subjective evaluation of their @entity9467 , indoors and outdoors, at baseline and at 1, 4 and 13 weeks after injection. The mean score for symptoms indoors and outdoors was calculated. RESULTS: Fourteen @entity1 agreed to take part in the study. Subjective @entity9467 improved in 8 out of the 11 @entity1 (72.7%) who completed 13 weeks of follow-up. Schirmer test results showed objective reduction in tearing from baseline but did not strongly correlate with the subjective @entity9467 . Transient mild @entity1736 and @entity892 were experienced by two @entity1 . CONCLUSION: The results from this small pilot study are encouraging, although larger, controlled trials are needed to assess the optimal dose of BTX-A, its long-term efficacy and safety, and the role of multiple injections.

The use of botulinum toxin A in the XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1736 :: ('MESH:D001763', 'Disease') :: ['ptosis'] @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia'] @entity9467 :: ('MESH:D007766', 'Disease') :: ['epiphora symptoms', 'epiphora', 'epiphora scores']
@entity9467 :: (MESH:D007766,Disease) :: ['treatment of functional epiphora']
